Agmatine Sulfate
Research reviewed: Up until 03/2026
Agmatine Sulfate (Agmatine) is a dietary supplement with 10 published peer-reviewed studies involving 240 participants, researched for Neuropathic Pain, Depression & Mood, Neuroprotection and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Neuropathic Pain
ModerateDepression & Mood
ModerateNeuroprotection
WeakClinical trials
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Neuropathic Pain
To evaluate dietary agmatine sulfate for lumbar disc-associated radiculopathy
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate dietary agmatine sulfate for lumbar disc-associated radiculopathy
Dose
1.335 g/day
Participants
61 patients with lumbar disc radiculopathy
Duration
14 days open-label + 2 weeks RCT
Results
Agmatine significantly reduced pain scores (26.7% improvement vs 6.0% placebo) and improved quality of life by 70.8%. Treatment was safe.
How They Measured It
VAS pain score, quality of life measures
To assess agmatine sulfate in painful small fiber neuropathy resistant to conventional treatment
Study Type
Pilot open-label case series
Purpose
To assess agmatine sulfate in painful small fiber neuropathy resistant to conventional treatment
Dose
2.67 g/day
Participants
17 patients with small fiber neuropathy
Duration
3 months
Results
Significant reduction in neuropathic pain intensity. Mean NRS pain score reduced from 7.2 to 3.8 in patients resistant to conventional analgesics.
How They Measured It
NRS pain intensity, neurological assessment
To investigate agmatine mechanism in neuropathic pain via NMDA receptor antagonism
Study Type
Animal study
Purpose
To investigate agmatine mechanism in neuropathic pain via NMDA receptor antagonism
Dose
40 mg/kg
Participants
Rodent neuropathic pain model
Duration
21 days
Results
Agmatine dose-dependently reduced neuropathic pain behaviors by blocking NMDA receptors and inhibiting nitric oxide synthesis.
How They Measured It
Paw withdrawal threshold, NMDA receptor binding assays
Depression & Mood
To assess antidepressant effect of exogenous agmatine in MDD patients
Study Type
Pilot clinical study
Purpose
To assess antidepressant effect of exogenous agmatine in MDD patients
Dose
Oral agmatine + parachlorophenylalanine challenge
Participants
12 MDD patients
Duration
6 weeks
Results
Antidepressant effect of agmatine confirmed and not reversed by serotonin depletion, confirming non-serotonergic mechanism (NMDA antagonism). PMID: 25287313
How They Measured It
Hamilton Depression Rating Scale
To evaluate agmatine on depression/anxiety via nitrergic signalling in chronic stress model
Study Type
Animal study
Purpose
To evaluate agmatine on depression/anxiety via nitrergic signalling in chronic stress model
Dose
20 mg/kg
Participants
Rodent model
Duration
28 days
Results
Agmatine attenuated depression/anxiety-like behaviours, reduced corticosterone, and elevated BDNF levels. Nitrergic pathway confirmed as mechanism.
How They Measured It
FST, EPM, BDNF, serum corticosterone
To evaluate agmatine as a novel therapeutic strategy for depression
Study Type
Systematic review
Purpose
To evaluate agmatine as a novel therapeutic strategy for depression
Dose
Various
Participants
Literature review
Duration
N/A
Results
Agmatine demonstrated antidepressant activity via NMDA antagonism, NOS inhibition, imidazoline receptor activation, and monoamine modulation. Future clinical trials encouraged.
How They Measured It
Review of preclinical and clinical evidence
Neuroprotection
To investigate agmatine neuroprotection against glutamate excitotoxicity
Study Type
In vitro study
Purpose
To investigate agmatine neuroprotection against glutamate excitotoxicity
Dose
0.1-1 mM
Participants
Primary neuronal cultures
Duration
24 hours
Results
Agmatine significantly protected neurons against glutamate excitotoxicity by blocking NMDA receptors and reducing nitric oxide production.
How They Measured It
Cell viability, NMDA receptor activity assays
To investigate agmatine in mouse model of Alzheimer's disease
Study Type
Animal study
Purpose
To investigate agmatine in mouse model of Alzheimer's disease
Dose
40 mg/kg
Participants
Alzheimer's disease mouse model
Duration
60 days
Results
Agmatine ameliorated depression-like behavior and reduced hippocampal neuroinflammation. Suggested neuroprotective role in neurodegeneration.
How They Measured It
Cognitive tests, neuroinflammation markers
To summarize agmatine's pharmacology as an endogenous neuromodulator
Study Type
Review
Purpose
To summarize agmatine's pharmacology as an endogenous neuromodulator
Dose
Various
Participants
N/A
Duration
N/A
Results
Agmatine acts as endogenous neuromodulator via NMDA blockade, imidazoline activation, and nitric oxide modulation. Multi-target agent for neuropathic pain and neurodegenerative disease.
How They Measured It
Comprehensive literature review
Clinical trials
To investigate the effects of Agmatine Sulfate in lubiprostone in chronic kidney disease: insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial.
Study Type
Randomized, double-blind, placebo-controlled
Purpose
To investigate the effects of Agmatine Sulfate in lubiprostone in chronic kidney disease: insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial.
Dose
Agmatine Sulfate (dose not specified)
Participants
150 participants
Duration
24 weeks
Results
d its slope in the 16-microgram group. Mild-to-moderate gastrointestinal events occurred in the placebo and 16-microgram groups. Multiomics analysis revealed that lubiprostone modulated the gut microbial agmatine pathway and increased spermidine levels, thereby improving renal mitochondrial function. Lubiprostone is a previously unknown and safe therapeutic option to mitigate renal decline in CKD.
How They Measured It
See study for outcome measures
Frequently Asked Questions
Common questions about Agmatine Sulfate research
There are currently 10 peer-reviewed studies on Agmatine Sulfate (Agmatine), involving 240 total participants. Research covers Neuropathic Pain, Depression & Mood, Neuroprotection and 1 more areas. The overall evidence strength is rated as Moderate.
The evidence is currently rated as "Moderate Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (4 human studies, 3 animal studies), and reported outcomes.
Agmatine Sulfate has been researched for: Neuropathic Pain, Depression & Mood, Neuroprotection, Clinical trials. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 4 out of 10 studies are human trials. The remaining 3 are animal studies. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
